SpyGlass Pharma Files for IPO to Raise Up to $100 Million for Chronic Eye Disease Implant Therapies

Jiemian News APP learned that SpyGlass Pharma (SGP.US), a biotechnology company currently in the Phase 3 clinical trial stage, focuses on developing implantable medical devices for the treatment of chronic eye diseases. Last Friday, the company officially submitted an application for its initial public offering (IPO) to the U.S. Securities and Exchange Commission (SEC), planning to raise up to $100 million.

It is reported that SpyGlass Pharma is a late-stage biopharmaceutical company focused on chronic eye diseases, dedicated to developing long-acting drug delivery solutions for sustained disease control and vision protection. Its lead product candidate is the Bimatoprost Eluting Implant System (BIM-IOL System), which consists of a novel proprietary drug-eluting component attached to an intraocular lens (IOL). Designed for implantation during routine cataract surgery, the system aims to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

The BIM-IOL system is designed to continuously release bimatoprost for up to three years, a prostaglandin analog (PGA) that was approved by the U.S. Food and Drug Administration (FDA) in 2001 for topical treatment to reduce high intraocular pressure in patients with OAG or OHT. Additionally, the company is developing a non-IOL-based annular sustained-release implant containing bimatoprost, which it believes can be implanted independently, offering an opportunity for re-treatment in patients who have previously undergone BIM-IOL system treatment and providing long-term care for OAG or OHT patients who have already had cataract surgery.

Headquartered in Aliso Viejo, California, the company was founded in 2019 and plans to list on the Nasdaq under the ticker symbol SGP. SpyGlass Pharma confidentially submitted its IPO application on September 26, 2025. Jefferies, RBC Capital Markets, Citigroup, and Stifel are the joint lead underwriters for the offering. The specific pricing terms of the deal have not been disclosed.